Core Viewpoint - Connoa-B (02162) shares rose nearly 3%, currently up 2.24% at HKD 57, with a trading volume of HKD 19.71 million, following the announcement of CM336's fast track designation by the FDA for treating autoimmune hemolytic anemia (AIHA) and immune thrombocytopenia (ITP) [1] Group 1 - Connoa and Ouro Medicines Ltd announced that their BCMA×CD3 dual antibody CM336 (OM336) received fast track designation (FTD) from the FDA for the treatment of AIHA and ITP [1] - The fast track designation highlights the urgent need for innovative treatment options for these diseases and underscores the therapeutic potential of CM336 in autoimmune diseases [1] - CM336 has also received orphan drug designation (ODD) from the FDA for the treatment of AIHA and ITP [1] Group 2 - Connoa entered into an exclusive licensing agreement with Ouro Medicines Ltd, granting Ouro exclusive rights to research, develop, manufacture, register, and commercialize CM336 globally, excluding mainland China, Hong Kong, Macau, and Taiwan [1]

Group 1 - The Nipah virus, classified as a high-priority pathogen by the World Health Organization, has recently caused a new outbreak in eastern India, with a mortality rate ranging from 40% to 75% [1][4] - As of now, West Bengal, India, has reported 5 confirmed cases, with nearly 100 individuals under home quarantine [1][4] - Initial investigations suggest that the first patient, a nurse, may have contracted the virus from contaminated fresh date palm juice [1][4] Group 2 - The outbreak has affected travel plans, with some Chinese tourists canceling trips to Southeast Asia due to concerns over the Nipah virus [3][6] - Health monitoring measures have been intensified at Phuket International Airport for Indian tourists, reflecting the potential impact on tourism [3][4] - Experts indicate that while the risk of the Nipah virus entering China exists, it is currently considered manageable [7][10] Group 3 - Several companies in China have developed domestic testing kits for the Nipah virus, which can assist in monitoring and controlling the outbreak [11] - Companies like Shuoshi Biological and Cap Bio have introduced nucleic acid testing kits to support public health efforts [11] - The development of targeted drugs and vaccines for the Nipah virus is challenging due to the virus's high danger level and the lack of sufficient clinical trial cases [12]

Core Viewpoint - Connoa-B (02162) has seen a nearly 3% increase in stock price, currently trading at 57 HKD, following the announcement of its drug CM336 receiving Fast Track Designation from the FDA for treating autoimmune hemolytic anemia (AIHA) and immune thrombocytopenia (ITP) [1] Group 1 - Connoa and Ouro Medicines Ltd have jointly announced that their BCMA×CD3 dual antibody CM336 (OM336) has been granted Fast Track Designation by the FDA for the treatment of AIHA and ITP [1] - The Fast Track Designation highlights the urgent need for innovative treatment options for these diseases and underscores the therapeutic potential of CM336 in autoimmune diseases [1] - CM336 has also received Orphan Drug Designation (ODD) from the FDA for the treatment of AIHA and ITP, indicating its significance in addressing rare diseases [1] Group 2 - Connoa has entered into an exclusive licensing agreement with Ouro Medicines Ltd, granting them exclusive rights to research, develop, manufacture, register, and commercialize CM336 globally, excluding mainland China, Hong Kong, Macau, and Taiwan [1]

财务数据显示，公司近年来经营保持稳健增长。2022至2024年，营业收入自15.27亿元增至28.17亿元， 归属于母公司股东的净利润从2.87亿元攀升至8.28亿元；2025年1-9月，公司已实现营业收入24.80亿 元，净利润6.66亿元。截至2025年9月末，公司总资产37.86亿元，资产负债率20.52%，流动比率3.84 倍，速动比率3.20倍，偿债能力良好；应收账款周转率4.17次/年，存货周转率0.77次/年。公司最近三年 累计现金分红5.06亿元，占近三年年均可分配利润的90.83%。 南方财经1月27日电，特宝生物(688278.SH)于2026年1月26日披露向不特定对象发行可转换公司债券预 案，拟募集资金不超过15.33亿元，用于三大核心项目：新药研发项目拟投入6.71亿元，生物技术创新融 合中心建设项目拟投入4.62亿元，创新药物生产改扩产线建设项目拟投入4.01亿元。募集资金将优先用 于保障核心业务升级与产能扩张。 ...

Group 1 - The core point of the news is that Shutaishen's stock price dropped by 5.2% to 26.60 CNY per share, with a trading volume of 383 million CNY and a turnover rate of 3.13%, resulting in a total market capitalization of 12.709 billion CNY [1] - Shutaishen (Beijing) Biopharmaceutical Co., Ltd. was established on August 16, 2002, and went public on April 15, 2011. The company primarily engages in the research, production, and sales of biological products and some chemical drugs [1] - The main revenue composition of Shutaishen includes 59.17% from injectable mouse nerve growth factor (Sutai), 33.19% from compound polyethylene glycol electrolyte powder, and 7.63% from other products [1] Group 2 - From the perspective of major fund holdings, one fund under CITIC Prudential has heavily invested in Shutaishen. The CITIC Prudential Zhirui Mixed A Fund (003432) increased its holdings by 60,000 shares in the fourth quarter, bringing the total to 355,000 shares, which accounts for 4% of the fund's net value, making it the sixth-largest holding [2] - The CITIC Prudential Zhirui Mixed A Fund was established on October 21, 2016, with a current size of 134 million CNY. Year-to-date returns are 1.83%, ranking 6888 out of 8861 in its category; the one-year return is 7.03%, ranking 6921 out of 8126; and the return since inception is 72.96% [2] Group 3 - The fund managers of CITIC Prudential Zhirui Mixed A Fund are Wang Rui and Zhu Huiling. Wang Rui has a tenure of 10 years and 276 days, with a total fund asset size of 5.719 billion CNY, achieving a best return of 253.09% and a worst return of -32.84% during his tenure [3] - Zhu Huiling has a tenure of 301 days, managing a total fund asset size of 242 million CNY, with a best return of 7.37% and a worst return of 7.29% during her tenure [3]

中国经济网北京1月27日讯 特宝生物(688278.SH)昨晚披露向不特定对象发行可转换公司债券预案， 本次发行证券的种类为可转换为公司A股股票的可转换公司债券。本次可转换公司债券及未来转换的公 司A股股票将在上海证券交易所科创板上市。本次发行的可转换公司债券按面值发行，每张面值为人民 币100.00元。本次发行的可转换公司债券的期限为自发行之日起6年。 本次发行的可转换公司债券票面利率的确定方式及每一计息年度的最终利率水平，由公司股东会授 权公司董事会（或董事会授权人士）在发行前根据国家政策、市场状况和公司具体情况与保荐机构（主 承销商）协商确定。本次可转换公司债券在发行完成前如遇银行存款利率调整，则由公司股东会授权董 事会（或由董事会授权人士）对票面利率作相应调整。 本次发行的可转换公司债券的初始转股价格不低于募集说明书公告日前二十个交易日公司A股股票 交易均价和前一个交易日公司A股股票交易均价，具体初始转股价格由公司股东会授权公司董事会（或 董事会授权人士）在发行前根据市场和公司具体情况与保荐机构（主承销商）协商确定。 本次可转债的具体发行方式由公司股东会授权董事会（或董事会授权人士）与保荐机构（主承销 ...

Core Viewpoint - The company Valiant Pharmaceuticals (维立志博-B, 09887) has seen a significant stock increase following the announcement of its core product, LBL-024, receiving orphan drug designation from the European Commission for the treatment of extra-pulmonary neuroendocrine carcinoma (EP-NEC) [1] Group 1: Product Development - LBL-024 has reached an important milestone in its global development process with the orphan drug designation [1] - The product is currently undergoing Phase II or registration clinical trials for three indications: non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), and EP-NEC, showcasing first-in-class (FIC) or best-in-class (BIC) potential [1] Group 2: Regulatory Approvals - On January 14, LBL-024 received Fast Track designation from the U.S. FDA for the treatment of extra-pulmonary neuroendocrine carcinoma [1] - LBL-024 is a bispecific antibody that targets both PD-L1 and 4-1BB, making it the first targeted therapy for 4-1BB receptor in the registration clinical stage for extra-pulmonary neuroendocrine carcinoma [1]

Core Viewpoint - Valiant Bio-B (09887) has seen a significant stock increase, rising over 6% and currently trading at 62.2 HKD, with a transaction volume of 24.4 million HKD, following the announcement of its core product, Valiantxin (LBL-024), receiving orphan drug designation from the European Commission for the treatment of extra-pulmonary neuroendocrine carcinoma (EP-NEC) [1] Group 1 - Valiantxin has reached an important milestone in its global development process, now in Phase II or registration clinical trials for three indications: non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), and EP-NEC, demonstrating first-in-class (FIC) or best-in-class (BIC) potential [1] - On January 14, Valiantxin was granted Fast Track designation by the FDA for the treatment of extra-pulmonary neuroendocrine carcinoma, marking it as the first targeted therapy for the 4-1BB receptor to reach the registration clinical stage globally [1]

Summary of Key Points from Conference Call Records Company: Junshi Biosciences (君实生物) Industry: Biopharmaceuticals Core Insights and Arguments - **Discovery of VV116**: The Wuhan Institute of Virology published findings on January 26, indicating that VV116 exhibits high inhibitory activity against the Nipah virus, including strains NiV-M and NiV-B [1] - **Mechanism of Action**: VV116, a novel oral nucleoside antiviral drug, demonstrated significant suppression of the Nipah virus in both its active form and its metabolites [1] - **Efficacy in Animal Models**: In a lethal dose infection model using golden hamsters, VV116 administered at a dose of 400 mg/kg increased the survival rate of the experimental animals to 66.7% and significantly reduced viral loads in target organs such as the lungs, spleen, and brain [1] Additional Important Information - **Broad Pipeline**: Junshi Biosciences has a wide-ranging portfolio that includes antiviral drugs, small nucleic acids, bispecific antibodies, antibody-drug conjugates (ADC), cytokines, and vaccines [1] - **Underestimation of Company Value**: The company is considered severely undervalued, with projections indicating strong performance in 2025. This could lead to a positive feedback loop for the company [2] - **Accelerated Innovation Pipeline**: Junshi currently has over 50 products in development, with 5 products in Phase III clinical trials or registration stages (IL-17, subcutaneous Trelagliptin, PI3K, Claudin18.2 ADC, BTLA) and 5 products in Phase II clinical trials, nearing or entering Proof of Concept (PoC) stages (PD-1/VEGF, EGFR/HER3 ADC, SNA spherical small nucleic acids, DKK1 monoclonal antibody, CD20/CD3 bispecific antibody) [2] - **Potential for Global Expansion**: There is speculation that if Junshi can successfully enter international markets, it may become the next billion-dollar biopharmaceutical company [2]

公司预计2025年实现营业收入42亿元，与上年同期相比，将增加30.06亿元左右，相比上年涨幅约251.76%； 预计实现归母净利润29.00亿元左右，与上年同期相比，将增加21.95亿元左右，相比上年同期涨幅约311.35%。 【国泰海通医药】三生国健2025年业绩预告 公司预计2025年实现营业收入42亿元，与上年同期相比，将增加30.06亿元左右，相比上年涨幅约251.76%； 预计实现归母净利润29.00亿元左右，与上年同期相比，将增加21.95亿元左右，相比上年同期涨幅约311.35%。 预计实现扣非归母净利润28.00亿元左右，与上年同期相比，将增加25.54亿元左右，相比上年同期涨幅约 1，038.21% 【国泰海通医药】三生国健2025年业绩预告 707资产权分配比例为三生国健30%，沈阳三生70%。 据测算，三生国健最多可获得3.75亿美元的首付款和14.4亿美元的里程碑付款，并获得特许权使用费 预计实现扣非归母净利润28.00亿元左右，与上年同期相比，将增加25.54亿元左右，相比上年同期涨幅约 1，038.21%。 公司收到辉瑞公司就707项目支付的授权许可首付款并相应确认收入约28.9 ...